A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)
Case Comprehensive Cancer Center
Case Comprehensive Cancer Center
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Wake Forest University Health Sciences
University of Nebraska
University of Nebraska
University of Nebraska
University of Nebraska
Mayo Clinic
Memorial Sloan Kettering Cancer Center
Northwestern University
Roswell Park Cancer Institute
Universität des Saarlandes
Mayo Clinic
Jonsson Comprehensive Cancer Center
Jonsson Comprehensive Cancer Center
Case Comprehensive Cancer Center
Mayo Clinic
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
University of Wisconsin, Madison
University of Wisconsin, Madison
Mayo Clinic
Roswell Park Cancer Institute
Mayo Clinic
Roswell Park Cancer Institute
Mayo Clinic
University of Chicago
Chonbuk National University Hospital
Swiss Cancer Institute
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Wake Forest University Health Sciences
Wake Forest University Health Sciences
Ohio State University Comprehensive Cancer Center
Virginia Commonwealth University
Ohio State University Comprehensive Cancer Center
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Wake Forest University Health Sciences
Wake Forest University Health Sciences
Massachusetts General Hospital
University of Washington
Fred Hutchinson Cancer Center
University of Washington
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center